York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high-quality and effective rapid tests, notes that a judgement in relation to the
Avacta Group PLC (AIM:AVCT) Phase I study of AVA6000 advances to fourth cohort
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Avacta Group PLC (AIM:AVCT) Second dose escalation in phase 1 trial of AVA6000
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Abingdon Health PLC (AIM:ABDX) Supply agreement for Abingdon COVID-19 tests
Purchase of 10m Abingdon Health Simply Test COVID-19 antigen tests; subject to Taiwan FDA approval of test
Avacta Group PLC (AIM:AVCT) Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), a clinical-stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Abingdon Health PLC (AIM:ABDX) DeepVerge Testing Services Framework Agreement
York, U.K. 30 May 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that it has signed a Testing
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Significant contract signed to manufacture lateral flow device components
Avacta Group PLC (AIM:AVCT) AffyXell expands partnership with GenScript ProBio
AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies
Abingdon Health PLC (AIM:ABDX) Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme disease lateral flow self-test
Avacta Group PLC (AIM:AVCT) London Therapeutics headquarters established
Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus
Avacta Group PLC (AIM:AVCT) AffyXell milestone and increased equity stake
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a